Aripiprazole – 25 mg

Brand:
Cayman
CAS:
129722-12-9
Storage:
-20
UN-No:
Non-Hazardous - /

Aripiprazole is an atypical antipsychotic.{47557} It is a partial agonist at dopamine D2, D2L, and D3 receptors (Kis = 3.3, 0.74, 9.7 nM, respectively), a partial agonist of the serotonin (5-HT) receptor subtype 5-HT1A (Ki = 5.6 nM), and an inverse agonist of 5-HT2B receptors (Ki = 0.36 nM). It is functionally selective at the dopamine D2 receptor with cell-type- and function-selective activities. Aripiprazole inhibits disruptions in prepulse inhibition induced by phencyclidine in mice when administered at doses of 5 and 10 mg/kg.{47558} Formulations containing aripiprazole have been used in the treatment of schizophrenia, bipolar mania or mixed episodes, and Tourette’s disorder.  

 

Available on backorder

SKU: 19989 - Category:

Description

An atypical antipsychotic; a partial agonist at dopamine D2, D2L, and D3 receptors (Kis = 3.3, 0.74, 9.7 nM, respectively), a partial agonist of 5-HT1A receptors (Ki = 5.6 nM), and an inverse agonist of 5-HT2B receptors (Ki = 0.36 nM); inhibits disruptions in prepulse inhibition induced by phencyclidine in mice when administered at doses of 5 and 10 mg/kg


Formal name: 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone

Synonyms:  OPC 14597|OPC 31

Molecular weight: 448.4

CAS: 129722-12-9

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Receptor Pharmacology|Inverse Agonists||Research Area|Neuroscience|Behavioral Neuroscience|Bipolar Disorder||Research Area|Neuroscience|Behavioral Neuroscience|Depression||Research Area|Neuroscience|Behavioral Neuroscience|Schizophrenia & Psychosis